Schoemaker H, Pimoule C, Arbilla S, Scatton B, Javoy-Agid F, Langer S Z
Naunyn Schmiedebergs Arch Pharmacol. 1985 May;329(3):227-35. doi: 10.1007/BF00501873.
The binding of radiolabelled cocaine, an inhibitor of dopamine uptake, to the post-mortem human putamen was studied and compared to that in the rat striatum. Saturation analysis of [3H]cocaine binding to the human putamen revealed the presence of a high affinity component of binding with a Kd of 0.21 mumol/l and a Bmax of 1.47 pmol/mg protein. In addition a low affinity component (Kd = 26.4 mumol/l) was demonstrated, having a Bmax of 42.2 pmol/mg protein. Also in the rat striatum [3H]cocaine binding was both of high affinity (Kd = 0.36 mumol/l, Bmax = 5.56 pmol/mg protein) and low affinity (Kd = 25.9 mumol/l, Bmax = 35.6 pmol/mg protein). A pharmacological characterisation of high affinity [3H]cocaine binding to rat striatal membranes clearly indicates an association with the neuronal dopamine transporter. The IC50 values of 8 selected drugs for inhibition of [3H]cocaine binding in the rat striatum were highly significantly correlated with their potency to inhibit [3H]dopamine uptake into slices of the rat striatum. [3H]Cocaine binding was stereospecifically inhibited by (+)nomifensine and (+)diclofensine which were 50-80-fold more active than their respective (-)isomers. Drugs with dopamine releasing activity were more potent at inhibiting [3H]dopamine uptake than at competing for the high affinity site of [3H]cocaine binding. A highly significant correlation was found between IC50 values for [3H]cocaine binding in the rat striatum and the human putamen. Further evidence in support of an association of [3H]cocaine binding in the rat striatum with the dopamine transporter was obtained from lesion studies. Thus, intranigral 6-hydroxydopamine administration produced a marked (67%) decrease in striatal [3H]cocaine binding.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了放射性标记的可卡因(一种多巴胺摄取抑制剂)与人死后壳核的结合情况,并与大鼠纹状体中的结合情况进行了比较。对[3H]可卡因与人壳核的结合进行饱和分析,结果显示存在一种高亲和力结合成分,其解离常数(Kd)为0.21μmol/L,最大结合容量(Bmax)为1.47pmol/mg蛋白质。此外,还证实存在一种低亲和力成分(Kd = 26.4μmol/L),其Bmax为42.2pmol/mg蛋白质。在大鼠纹状体中,[3H]可卡因结合同样具有高亲和力(Kd = 0.36μmol/L,Bmax = 5.56pmol/mg蛋白质)和低亲和力(Kd = 25.9μmol/L,Bmax = 35.6pmol/mg蛋白质)。对大鼠纹状体膜上高亲和力[3H]可卡因结合的药理学特性分析清楚地表明其与神经元多巴胺转运体有关。8种选定药物对大鼠纹状体中[3H]可卡因结合的抑制作用的半数抑制浓度(IC50)值与其抑制[3H]多巴胺摄取到大鼠纹状体切片中的效力高度显著相关。[3H]可卡因结合被(+)诺米芬辛和(+)双氯芬辛立体特异性抑制,它们的活性比各自的(-)异构体高50 - 80倍。具有多巴胺释放活性的药物在抑制[3H]多巴胺摄取方面比竞争[3H]可卡因结合的高亲和力位点更有效。在大鼠纹状体和人壳核中[3H]可卡因结合的IC50值之间发现了高度显著的相关性。从损伤研究中获得了进一步支持大鼠纹状体中[3H]可卡因结合与多巴胺转运体相关的证据。因此,向黑质内注射6 - 羟基多巴胺导致纹状体中[3H]可卡因结合显著降低(67%)。(摘要截短于250字)